Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Pharm Res. 2011 Sep;34(9):1403-7. doi: 10.1007/s12272-011-0921-6.

Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.

Author information

  • 1College of Pharmacy, Dongguk University, Goyang 410-820, Korea. choongholee@dongguk.edu

Abstract

Chronic hepatitis C virus (HCV) infection is responsible for development of liver cirrhosis and hepatocellular carcinoma. In addition to PEGylated interferon-α, ribavirin, and HCV NS3 protease inhibitors, recently identified HCV NS5A inhibitors such as BMS-790052 showed a great promise in clinical trials as another new class of direct-acting anti-HCV therapeutics with a distinct mechanism of action. This clinical proof-of-concept study with NS5A inhibitors demonstrated that small molecules targeting a viral protein without any known enzymatic activity can also have profound antiviral effects. In conclusion, NS5A inhibitors will serve as a valuable component of future therapy for HCV patients.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk